Fuller & Thaler Asset Management, Inc. Exelixis, Inc. Transaction History
Fuller & Thaler Asset Management, Inc.
- $25.4 Billion
- Q1 2025
A detailed history of Fuller & Thaler Asset Management, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Fuller & Thaler Asset Management, Inc. holds 7,795,074 shares of EXEL stock, worth $335 Million. This represents 1.13% of its overall portfolio holdings.
Number of Shares
7,795,074
Previous 7,630,940
2.15%
Holding current value
$335 Million
Previous $254 Million
13.26%
% of portfolio
1.13%
Previous 0.99%
Shares
25 transactions
Others Institutions Holding EXEL
# of Institutions
613Shares Held
257MCall Options Held
1.57MPut Options Held
730K-
Black Rock Inc. New York, NY33.5MShares$1.44 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA28.7MShares$1.23 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA22.5MShares$970 Million4.78% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny14.8MShares$638 Million0.88% of portfolio
-
State Street Corp Boston, MA11.8MShares$507 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $13.9B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...